Clinical Trial Update: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GP2013 in rheumatoid arthritis patients refractory to or intolerant of standard therapy, reported results after Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GP2013 (rituximab biosimilar)

Snippet

Sponsor: Sandoz | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-24